Aptose Reports Results for the Third Quarter 2024
November 08, 2024 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Announces Results from Special Meeting of Shareholders
September 05, 2024 16:15 ET
|
Aptose Biosciences, Inc.
Aptose Announces Results from Special Meeting of Shareholders
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
August 30, 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose Receives $10 Million Through a Facility Agreement with Hanmi;
Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Aptose Announces Adjournment of its Special Meeting of Shareholders
August 15, 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose Announces Adjournment of its Special Meeting of Shareholders
Aptose Reports Results for the Second Quarter 2024
August 08, 2024 17:06 ET
|
Aptose Biosciences, Inc.
Aptose Reports Results for the Second Quarter 2024
Aptose Announces Results from Annual and Special Meeting of Shareholders
June 18, 2024 17:30 ET
|
Aptose Biosciences, Inc.
Aptose Announces Results from Annual and Special Meeting of Shareholders
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 03, 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market
Under Nasdaq Rules
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 31, 2024 08:00 ET
|
Aptose Biosciences, Inc.
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Aptose Reports Results for the First Quarter 2024
May 14, 2024 16:01 ET
|
Aptose Biosciences, Inc.
Aptose Reports Results for the First Quarter 2024
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
May 06, 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose to Report First Quarter 2024 Financial Results and
Provide Clinical Strategy Update on Tuesday, May 14, 2024